We are especially impressed with the company s Cobalaminbased oral drug delivery system. Both oral insulin and human growth hormone have achieved unprecedented oral bioavailability in animal models. Current share price is undervalued. We encourage investors accumulate the company s shares. Our six to twelve-month price target is $8.
Updated Apr 20, 2018 03:58 PM ET
F Value | F Growth | F Momentum | F VGM
Zacks Style Scores Education - Learn more about the Zacks Style Scores
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank